Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Alexandre V. Hirayama(University of Washington), Cameron J. Turtle(The University of Sydney), Erik L. Kimble(University of Washington), David G. Maloney(Fred Hutch Cancer Center), Delaney R. Kirchmeier(Fred Hutch Cancer Center), Henna A Di(Fred Hutch Cancer Center), Qian Wu(Cancer Research Center), Aude G. Chapuis(University of Washington), Brian G. Till(University of Washington), Mazyar Shadman(University of Washington), Salvatore Fiorenza(Fred Hutch Cancer Center), Filippo Milano(Fred Hutch Cancer Center), Jenna Voutsinas(Fred Hutch Cancer Center), Hans‐Peter Kiem(Fred Hutch Cancer Center), Ryan D. Cassaday(University of Washington), Stanley R. Riddell(Fred Hutch Cancer Center), Damian J. Green(Sylvester Comprehensive Cancer Center), Barbara S. Pender, Jordan Gauthier(Seattle Cancer Care Alliance)
Cited by 6
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
|New England Journal of Medicine|1995|1.8k